AAAAI & ACAAI GUIDELINES Bundle (free trial)

Sublingual Immunotherapy

AAAAI & ACAAI GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/803814

Contents of this Issue

Navigation

Page 9 of 9

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2017 All rights reserved Disclaimer is Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. AAAAISUB17032a Source Greenhawt M, Oppenheimer J, Nelson MN, et al. Sublingual immunotherapy. Ann Allerg y Asthma Immunol. 2017;118(3):276-282.e2. Abbreviations AC, allergic conjunctivitis; ACE, angiotensin-converting enzyme; AIT, allergen immunotherapy; AR, allergic rhinitis; FDA, US Food and Drug Administration; GI, gastrointestinal; IFN-γ, interferon γ; IL, interleukin; MedDRA, Medical Dictionary for Regulatory Activities; NSAIDs, nonsteroidal anti-inflammatory drugs; OAS, oral allerg y syndrome; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; SS, summary statement Strength of Recommendation and Quality of Evidence Strength of Recommendation Quality of Evidence S Strong: Benefit clearly exceeds harm A / B Directly based on category I–II evidence M Moderate: Benefit exceeds harm but quality of evidence is not as strong B / C Directly based on category II–III evidence or extrapolated recommendation from category I evidence W Weak: Quality of evidence is suspect or there is little clear advantage to one approach vs. another D Directly based on category IV evidence or extrapolated recommendation from category I, II, or III evidence

Articles in this issue

Links on this page

Archives of this issue

view archives of AAAAI & ACAAI GUIDELINES Bundle (free trial) - Sublingual Immunotherapy